Published:
Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the Treatment of Postmenopausal Osteoporosis
COLLEGEVILLE, Pa., May 23 /PRNewswire/ -- Wyeth Pharmaceuticals, a
division of Wyeth (NYSE: WYE), announced today that the U.S. Food and Drug
Administration (FDA) issued an approvable letter on May 21 for bazedoxifene, a
selective estrogen receptor modulator, for the treatment of postmenopausal
osteoporosis. In the letter, the FDA requested information similar to that
outlined in its approvable letter for bazedoxifene's New Drug Application
(NDA) for the prevention of postmenopausal osteoporosis issued in December
2007. This included further analyses concerning the incidence of stroke and
venous thrombotic events. The Agency also identified specific questions
concerning data collection and reporting and requested additional source
documents.
"Today's action is in line with our expectations," says Gary L. Stiles,
M.D., Executive Vice President, Chief Medical Officer, Wyeth Pharmaceuticals.
"In our conference with the Agency earlier this year, they stated their desire
to convene an advisory committee to review the pending new drug applications
for both treatment and prevention of postmenopausal osteoporosis. We have
been working closely with the FDA to address their questions and we are
preparing a complete response which we expect to file by end of 2008. We
remain committed to pursuing bazedoxifene as an important new option for the
millions of postmenopausal women at risk for osteoporotic fracture."
About Osteoporosis
Osteoporosis is a disease characterized by low bone mass and structural
deterioration of bone tissue, leading to bone fragility and an increased risk
of fractures. According to the National Osteoporosis Foundation, the number
of women of menopausal age who have osteoporosis or are at risk for developing
the disease will increase from almost 30 million in 2002 to nearly 41 million
in 2020. Up to 20 percent of a woman's expected lifetime bone loss can occur
in the years immediately following menopause. The treatment of postmenopausal
osteoporosis could lead to significant improvement in the overall health for
millions of women worldwide as well as reduce costs associated with
postmenopausal osteoporosis-related fractures.
About Wyeth Pharmaceuticals
Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the
areas of women's health care, infectious disease, gastrointestinal health,
central nervous system, inflammation, transplantation, hemophilia, oncology,
vaccines and nutritional products.
Wyeth is one of the world's largest research-driven pharmaceutical and
health care products companies. It is a leader in the discovery, development,
manufacturing and marketing of pharmaceuticals, vaccines, biotechnology
products, nutritionals and non-prescription medicines that improve the quality
of life for people worldwide. The Company's major divisions include Wyeth
Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
The statements in this press release that are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied by such statements. These risks and uncertainties include, without
limitation, the inherent uncertainty of the timing and success of, and expense
associated with, research, development, regulatory approval and
commercialization of our products and pipeline products (including that there
can be no assurance that our pending new drug applications for bazedoxifene
will be approved or that the product will ever be successfully
commercialized); government cost-containment initiatives; restrictions on
third-party payments for our products; substantial competition in our
industry, including from branded and generic products; emerging data on our
products and pipeline products; the importance of strong performance from our
principal products and our anticipated new product introductions; the highly
regulated nature of our business; product liability, intellectual property and
other litigation risks and environmental liabilities; uncertainty regarding
our intellectual property rights and those of others; difficulties associated
with, and regulatory compliance with respect to, manufacturing of our
products; risks associated with our strategic relationships; economic
conditions including interest and currency exchange rate fluctuations; changes
in generally accepted accounting principles; trade buying patterns; the impact
of legislation and regulatory compliance; risks and uncertainties associated
with global operations and sales; and other risks and uncertainties, including
those detailed from time to time in our periodic reports filed with the
Securities and Exchange Commission, including our current reports on Form 8-K,
quarterly reports on Form 10-Q and annual report on Form 10-K, particularly
the discussion under the caption "Item 1A, Risk Factors" in our Annual Report
on Form 10-K for the year ended December 31, 2007, which was filed with the
Securities and Exchange Commission on February 29, 2008. The forward-looking
statements in this press release are qualified by these risk factors. We
assume no obligation to publicly update any forward-looking statements,
whether as a result of new information, future developments or otherwise.
SOURCE Wyeth Pharmaceuticals
Copyright © 2008, PRNewswire
Copyright © 2008, NewsBlaze,
Daily NewsTags: ,MTC,HEA,TRI,PDT,WOM,FDA,PA-Wyeth-Approvable
_ _Is your favorite bookmark site missing?
Ask for it.
Search News
Daily News
